Curesponse
PrivateLast Round
Series B
Nov 15, 2021
Total Funding Raised
$14M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Curesponse operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Series B round in November 2021.
Curesponse is a biotechnology company that has developed a cancer treatment testing platform designed to identify effective therapy for individual patients.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Curesponse Comparables
Compare Curesponse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| First Ascent Biomedical | 87% | |
| SageMedic Corp. | 87% | |
| Xilis | 82% |
For institutional investors. Book with your work email.
Curesponse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 15, 2021 | ||||
| Series A | Jun 5, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Curesponse Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| aMoon | Series A |
| NCL | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 38% MoM, reaching 962.
- Jun 5, 2025
Grew 20% QoQ from 15 to 18 employees.
For institutional investors. Book with your work email.
Curesponse Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Curesponse's valuation, stock price, and market status.
Is Curesponse a public or private company?
Curesponse is a private company.
What is the current stock price of Curesponse?
Curesponse is a private company, so its shares have no public market price. Caplight tracks Curesponse's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Curesponse worth (valuation)?
Valuation information for Curesponse is not publicly available.
Can I buy Curesponse stock?
Curesponse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Curesponse's last funding round?
Curesponse's most recent funding round was Series B on November 15, 2021.
Who are the main investors in Curesponse?
Key investors in Curesponse include aMoon, NCL.
Will Curesponse IPO soon?
No public IPO plans have been announced for Curesponse.
How can I track Curesponse secondary market activity?
Caplight tracks bids, offers, and trades in Curesponse's shares on secondary markets.